Table 2 Reasons of temozolomide or temozolomide plus bevacizumab maintenance therapy discontinuation
| N = 30 | |
|---|---|
| Tumor progression | 10 (33.3%) |
| Clinical deterioration without radiological tumor progression | 9 (30.0%) |
| Completeion of 12 cycles | 3 (10.0%) |
| Complication | 4 (13.3%) |
| Changing hospital for palliative care | 4 (13.3%) |